Abvc BiopharmaABVC
13F holders, Q1 2024 (March 31)8holders
$1.31avg. 13F price*
At the end of Q1 2024, 8 institutions reported holding Abvc Biopharma Inc. (ABVC) in their 13F filings. The largest holders were Chase Investment Counsel Corp. ($233K), Vanguard Group Inc. ($62K) and Geode Capital Management, LLC ($29K).
- Company
- Abvc Biopharma Inc.
- CUSIP
- 00091F304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $239K |
| Exits | 2 | $74K |
Ownership 8 holders
| Chase Investment Counsel Corp. | 0.09% | New | 178,377 | $233K |
| Vanguard Group Inc. | 0.00% | Add +72.3% | 46,947 | $62K |
| Geode Capital Management, LLC | 0.00% | Add +12.9% | 22,000 | $29K |
| Bank of America Corp. | 0.00% | New | 4,440 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +336.0% | 2,520 | $3K |
| Spotlight Asset Group, Inc. | 0.00% | No change | 100 | $131 |
| Wells Fargo & Company | 0.00% | Add +140.0% | 48 | $63 |
| Royal Bank of Canada | 0.00% | No change | 37 | $0 |
"% of holder's portfolio" is ABVC's weight in each manager's 13F, not the share of Abvc Biopharma Inc. the manager owns.